PH12022550338A1 - 2-hydroxycycloalkane-1-carbamoyl derivatives - Google Patents
2-hydroxycycloalkane-1-carbamoyl derivativesInfo
- Publication number
- PH12022550338A1 PH12022550338A1 PH1/2022/550338A PH12022550338A PH12022550338A1 PH 12022550338 A1 PH12022550338 A1 PH 12022550338A1 PH 12022550338 A PH12022550338 A PH 12022550338A PH 12022550338 A1 PH12022550338 A1 PH 12022550338A1
- Authority
- PH
- Philippines
- Prior art keywords
- hydroxycycloalkane
- carbamoyl derivatives
- compounds
- formula
- carbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019071921 | 2019-08-15 | ||
| PCT/EP2020/072865 WO2021028570A1 (en) | 2019-08-15 | 2020-08-14 | 2-hydroxycycloalkane-1-carbamoyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550338A1 true PH12022550338A1 (en) | 2023-02-06 |
Family
ID=72355943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550338A PH12022550338A1 (en) | 2019-08-15 | 2020-08-14 | 2-hydroxycycloalkane-1-carbamoyl derivatives |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12291519B2 (enExample) |
| EP (1) | EP4013751B1 (enExample) |
| JP (1) | JP7604457B2 (enExample) |
| KR (1) | KR102832308B1 (enExample) |
| CN (1) | CN114269737A (enExample) |
| AU (1) | AU2020329609B2 (enExample) |
| BR (1) | BR112021026829A2 (enExample) |
| CA (1) | CA3147454A1 (enExample) |
| ES (1) | ES3015725T3 (enExample) |
| HR (1) | HRP20250372T1 (enExample) |
| HU (1) | HUE070924T2 (enExample) |
| IL (1) | IL289197B2 (enExample) |
| MA (1) | MA56883B1 (enExample) |
| MX (1) | MX2022001789A (enExample) |
| PH (1) | PH12022550338A1 (enExample) |
| PL (1) | PL4013751T3 (enExample) |
| RS (1) | RS66695B1 (enExample) |
| TW (1) | TWI864071B (enExample) |
| UA (1) | UA128909C2 (enExample) |
| WO (1) | WO2021028570A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| CN115244045A (zh) * | 2019-12-24 | 2022-10-25 | 糖模拟物有限公司 | 抑制半乳凝素-3的c-糖苷酮、醚和醇 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) * | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| WO2022189459A2 (en) * | 2021-03-10 | 2022-09-15 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2022241183A1 (en) * | 2021-05-14 | 2022-11-17 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| WO2022250976A1 (en) * | 2021-05-28 | 2022-12-01 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (enExample) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) * | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CN109563119A (zh) | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| CA3062649A1 (en) * | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) * | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2020
- 2020-08-14 MA MA56883A patent/MA56883B1/fr unknown
- 2020-08-14 US US17/634,512 patent/US12291519B2/en active Active
- 2020-08-14 IL IL289197A patent/IL289197B2/en unknown
- 2020-08-14 JP JP2022508567A patent/JP7604457B2/ja active Active
- 2020-08-14 BR BR112021026829A patent/BR112021026829A2/pt unknown
- 2020-08-14 EP EP20767476.3A patent/EP4013751B1/en active Active
- 2020-08-14 PL PL20767476.3T patent/PL4013751T3/pl unknown
- 2020-08-14 KR KR1020227006817A patent/KR102832308B1/ko active Active
- 2020-08-14 MX MX2022001789A patent/MX2022001789A/es unknown
- 2020-08-14 PH PH1/2022/550338A patent/PH12022550338A1/en unknown
- 2020-08-14 RS RS20250349A patent/RS66695B1/sr unknown
- 2020-08-14 HR HRP20250372TT patent/HRP20250372T1/hr unknown
- 2020-08-14 HU HUE20767476A patent/HUE070924T2/hu unknown
- 2020-08-14 AU AU2020329609A patent/AU2020329609B2/en active Active
- 2020-08-14 CA CA3147454A patent/CA3147454A1/en active Pending
- 2020-08-14 UA UAA202200939A patent/UA128909C2/uk unknown
- 2020-08-14 WO PCT/EP2020/072865 patent/WO2021028570A1/en not_active Ceased
- 2020-08-14 TW TW109127800A patent/TWI864071B/zh active
- 2020-08-14 CN CN202080057325.7A patent/CN114269737A/zh active Pending
- 2020-08-14 ES ES20767476T patent/ES3015725T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12291519B2 (en) | 2025-05-06 |
| EP4013751B1 (en) | 2025-01-22 |
| EP4013751A1 (en) | 2022-06-22 |
| KR20220047585A (ko) | 2022-04-18 |
| HRP20250372T1 (hr) | 2025-06-06 |
| IL289197B1 (en) | 2025-10-01 |
| RS66695B1 (sr) | 2025-05-30 |
| MX2022001789A (es) | 2022-03-11 |
| HUE070924T2 (hu) | 2025-07-28 |
| JP2022544248A (ja) | 2022-10-17 |
| MA56883B1 (fr) | 2025-04-30 |
| UA128909C2 (uk) | 2024-11-20 |
| CA3147454A1 (en) | 2021-02-18 |
| TW202115039A (zh) | 2021-04-16 |
| KR102832308B1 (ko) | 2025-07-10 |
| AU2020329609B2 (en) | 2025-10-02 |
| US20220324847A1 (en) | 2022-10-13 |
| EP4013751C0 (en) | 2025-01-22 |
| JP7604457B2 (ja) | 2024-12-23 |
| BR112021026829A2 (pt) | 2022-02-22 |
| AU2020329609A1 (en) | 2022-02-24 |
| TWI864071B (zh) | 2024-12-01 |
| IL289197A (en) | 2022-02-01 |
| CN114269737A (zh) | 2022-04-01 |
| IL289197B2 (en) | 2026-02-01 |
| PL4013751T3 (pl) | 2025-05-19 |
| ES3015725T3 (en) | 2025-05-07 |
| WO2021028570A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MX2021004000A (es) | Derivados de piperidina. | |
| MX2023005039A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| MX418519B (es) | Inhibidores selectivos de jak1 | |
| TN2017000521A1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| MY209603A (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| MX394108B (es) | Derivados de indol n-sustituidos. | |
| PH12016500985A1 (en) | Use of benzimidazole-proline derivatives | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| GEP20247670B (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| PH12021553178A1 (en) | Pyridin-3-yl derivatives | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| MX2021004379A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| CL2023001138A1 (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3 | |
| MX2025000310A (es) | Nuevos derivados de espirociclohexano, composiciones farmaceuticas que los contienen y sus usos como inhibidores antiapoptoticos |